

Development of innovative anti-cancer treatment through tumor microenvironment-specific targeting

MedPacto, Inc.
MEDPACTO

ONCOLOGY	Preclinical
Product Type	rProtein
Indication	Solid tumors
Target	TGF- β and ***
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • MP010 selectively binds to ***, which is highly expressed in the tumor microenvironment (TME), and targets TGF-β preferentially in TME, a key mediator of tumor-induced immunosuppression. • By selectively inhibiting TGF-β activity within the TME, MP010 reprograms the TME and enhances anti-tumor immune responses.
Competitiveness	First-in-Class
Development Stage	Preclinical
Route of Administration	Intravenous

Any unauthorized distribution or reproduction of this material is strictly prohibited.